References
- Adhikari B, Kahende J, Malarcher A et al. Smoking-attributable mortality, years of potential life lost, and productivity losses – United States, 2000–2004. MMWR Morb. Mortal. Wkly Rep. 57(45), 1226–1228 (2008).
- Mariolis P, Rock VJ, Asman K et al. Tobacco use among adults – United States, 2005. MMWR Morb. Mortal. Wkly Rep. 55(42), 1145–1148 (2006).
- Shiffman S, Brockwell SE, Pillitteri JL et al. Use of smoking-cessation treatments in the United States. Am. J. Prev. Med. 34(2), 102–111 (2008).
- Aveyard P, West R. Managing smoking cessation. BMJ 335(7609), 37–41 (2007).
- Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. Rev. 4, CD006103 (2012).
- Silagy C, Lancaster T, Stead L et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 3, CD000146 (2004).
- Cokkinides VE, Ward E, Jemal A et al. Under-use of smoking-cessation treatments: results from the National Health Interview Survey, 2000. Am. J. Prev. Med. 28(1), 119–122 (2005).
- Ebbert JO, Glover ED, Shinozaki E et al. Predictors of smokeless tobacco abstinence. Am. J. Health Behav. 32(6), 735–740 (2008).
- Fiore MC, Jaen CR, Baker TB et al. Treating Tobacco Use and Dependence, 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2008.
- Boyle RG, Solberg LI, Magnan S et al. Does insurance coverage for drug therapy affect smoking cessation? Health Aff. (Millwood) 21(6), 162–168 (2002).
- Burns ME, Rosenberg MA, Fiore MC. Use and employer costs of a pharmacotherapy smoking-cessation treatment benefit. Am. J. Prev. Med. 32(2), 139–142 (2007).
- Menzin J, Lines LM, Marton J. Estimating the short-term clinical and economic benefits of smoking cessation: do we have it right? Expert Rev. Pharmacoecon. Outcomes Res. 9(3), 257–264 (2009).
- Bolin K, Wilson K, Benhaddi H et al. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation – results from four European countries. Eur. J. Public Health 19(6), 650–654 (2009).
- Howard P, Knight C, Boler A et al. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics 26(6), 497–511 (2008).
- Knight C, Howard P, Baker CL et al. The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model. Value Health 13(2), 209–214 (2010).
- Linden K, Jormanainen V, Linna M et al. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. Curr. Med. Res. Opin. 26(3), 549–560 (2010).
- Zeng F, Chen CI, Mastey V et al. Utilization management for smoking cessation pharmacotherapy: varenicline rejected claims analysis. Am. J. Manag. Care 16(9), 667–674 (2010).
- Zeng F, Chen CI, Mastey V, et al. Effects of copayment on initiation of smoking cessation pharmacotherapy: an analysis of varenicline reversed claims. Clin. Ther. 33(2), 225–234 (2011).
- Cooke CE, Glover ED, Xing S, Lee HY. Failure to obtain varenicline in members with pharmacy benefits. AJPB 3(3), e35–e41 (2011).
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol. 45(6), 613–619 (1992).
- Puig-Junoy J, Moreno-Torres I. Impact of pharmaceutical prior authorisation policies: a systematic review of the literature. Pharmacoeconomics 25(8), 637–648 (2007).
- MacKinnon NJ, Kumar R. Prior authorization programs: a critical review of the literature. J. Managed. Care. Pharm. 7, 297–302 (2001).
- Adams AS, Zhang F, LeCates RF et al. Prior authorization for antidepressants in Medicaid: effects among disabled dual enrollees. Arch. Intern. Med. 169(8), 750–756 (2009).
- Law MR, Lu CY, Soumerai SB et al. Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study. Clin. Ther. 32(4), 729–741 (2010).
- Lu CY, Law MR, Soumerai SB et al. Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study. Clin. Ther. 33(1), 135–144 (2011).
- Margolis JM, Johnston SS, Chu BC et al. Effects of a Medicaid prior authorization policy for pregabalin. Am. J. Manag. Care 15(10), e95–102 (2009).
- Lu CY, Soumerai SB, Ross-Degnan D et al. Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. Med. Care 48(1), 4–9 (2010).
- Myung SK, McDonnell DD, Kazinets G et al. Effects of Web- and computer-based smoking cessation programs: meta-analysis of randomized controlled trials. Arch. Intern. Med. 169(10), 929–937 (2009).
- McEwen A, West R. Do implementation issues influence the effectiveness of medications? The case of nicotine replacement therapy and bupropion in UK Stop Smoking Services. BMC Public Health 9, 9–28 (2009).
Websites
- Centers for Disease Control and Prevention [CDC]. Smoking & tobacco use: smoking cessation [online] 2011. www.cdc.gov/tobacco/data_statistics/fact_sheets/cessation/quitting/index.htm ( Accessed 21 December 2011)
- BTA Pharmaceuticals Inc. WELLBUTRIN XL – bupropion hydrochloride tablet, extended release, full prescribing information [online] 2011. www.rxlist.com/wellbutrin-xl-drug.htm ( Accessed 24 July 2012)